|1.||Gale, Michael: 2 articles (11/2015 - 02/2014)|
|2.||Samokhvalov, E I: 2 articles (01/2002 - 01/2000)|
|3.||Shaw, George M: 1 article (11/2015)|
|4.||Stoddard, Mark: 1 article (11/2015)|
|5.||Marcotrigiano, Joe: 1 article (11/2015)|
|6.||Li, Hui: 1 article (11/2015)|
|7.||Kell, Alison: 1 article (11/2015)|
|8.||Wending, Morgan Q S: 1 article (01/2015)|
|9.||Nasar, Farooq: 1 article (01/2015)|
|10.||Ladner, Jason T: 1 article (01/2015)|
05/15/2010 - "Two functionally distinct allelic forms of the Loop3 poly(U)-tract are prevalent in the human population, and it is conceivable that germ-line or somatic variations in this sequence could predispose individuals to development of malignancy, or provide a selectable growth advantage for tumor cells."
10/01/2009 - "Given the roles of Lin28 and let-7 in stem cell and cancer biology, we propose that such poly(U) polymerases are potential therapeutic targets."
11/01/1988 - "The results suggest that the protective activity against acid precipitation of poly (U) could prove to be a tumor marker for the early detection of cancer growth."
11/01/1988 - "Increased protective activity against acid precipitation of poly(U) in the serum of tumor-bearing mice."
05/01/1985 - "Poly(U) it appears that further development and application of this polynucleotide complex are certainly justified in terms of clinical use in cancer and perhaps in viral pathologies."
|2.||Stomach Neoplasms (Stomach Cancer)
01/01/1990 - "Thus, poly(A).poly(U) appears to be an effective agent when used postoperatively with chemotherapy in stomach cancers."
01/01/1987 - "Peripheral blood lymphocytes of operable stomach cancer patients were evaluated sequentially for their natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) activities before and after chemotherapy in association with polyadenylic.polyuridylic acid [poly(A).poly(U)]. "
01/01/1990 - "A randomized trial of polyadenylic.polyuridylic acid [poly(A).poly(U)] in addition to chemotherapy was undertaken in patients with stomach cancer following curative gastrectomy. "
11/01/1975 - "The therapeutic efficacy of polyadenlyic-polyuridylic acid (poly A-poly U) on the transplantable AKR leukemia varied with the dose of tumor cells implanted. "
04/01/1979 - "DBA/2 mice immunized with poly(A).poly(U) complexed with methylated bovine serum albumin and emulsified in Freund's complete adjuvant were protected against challenge with Friend leukemia virus. "
11/01/1975 - "The dependence of successful immunotherapy on adequate tumor burden as shown by the treatment of AKR leukemia with poly A-poly U."
12/01/1972 - "All ten RNA tumor viruses contained ribonuclease H activity which degraded the RNA of both the calf thymus hybrid and poly(A)-poly(dT), whereas only the ribonuclease H in the Moloney strain of murine sarcoma-leukemia virus and in RD-feline leukemia virus hydrolyzed the RNA strand of poly(U)-poly(dA). "
|4.||Chronic Hepatitis (Chronic Active Hepatitis)
03/01/1994 - "It can be concluded that poly(A).poly(U) seems to be effective in the treatment of chronic active hepatitis B and has an advantage of being free of significant side effects."
03/01/1994 - "In order to assess whether polyadenylic.polyuridylic acid [poly(A).poly(U)] can be used as a new therapeutic agent for the treatment of chronic hepatitis B, 19 patients with histologically proven chronic active hepatitis B were injected intravenously with 100-150 mg of poly(A).poly(U) weekly for six weeks. "
|5.||Breast Neoplasms (Breast Cancer)
04/01/1974 - "poly U) adjuvant immunotherapy in breast cancer treatment]."
01/01/1986 - "Second, the disease-free survival curves for adjuvant therapies of breast cancer were compared; Oncofrance trial: a combination of AVCF was superior to a combination of CMF in all the periods of the therapy; Lacour's trial: Poly A-Poly U was more effective than the control in the middle and late period; Bonadonna's trial: CMF was superior to the control in the early period. "
10/01/1985 - "The results of a randomized trial of polyadenylic-polyuridylic [poly(A).poly(U)] acid given as adjuvant treatment for operable breast cancer were reviewed after a mean follow-up period of 87 months. "
01/01/1978 - "Randomized trial with Poly A-Poly U as adjuvant therapy complementing surgery in patients with breast cancer: in vitro study of cellular immunity."
01/01/1988 - "[Therapeutic trial of Poly(A).Poly(U) adjuvant immunotherapy in operable cancer of the breast. "
|3.||Poly C (C, Poly)
|4.||RNA (Ribonucleic Acid)
|6.||Vinblastine (Vinblastine Sulfate)
|7.||Protein Kinases (Protein Kinase)
|1.||Drug Therapy (Chemotherapy)